Bacterial
Strain Screening
Rigorously screen diverse bacterial strains to identify those with optimal oncolytic potential and safety profiles.
Oncolytic bacteria therapy is a new cancer treatment that uses bacteria to target and kill cancer cells. Alfa Cytology's OncoBact™ platform employs engineered bacterial vectors to achieve tumor microenvironment-specific targeting. This breakthrough technology ensures precise therapeutic payload delivery for enhanced anti-cancer efficacy. Select for our one-stop oncolytic bacterial therapy development platform and embark on a hassle-free and efficient R&D journey. We also provide oncolytic bacteria-based combination therapy platform, and break the limitations of single-modality treatments. Through OncoBact™, we enhance treatment efficacy, offering innovative and comprehensive solutions to tackle complex cancer challenges.
Oncolytic bacteria therapy is an emerging cancer treatment strategy that uses genetically engineered, attenuated bacteria to precisely target and kill cancer cells. At the core of this approach are oncolytic bacteria, which have a natural ability to specifically target and lyse solid tumors while stimulating a robust host immune response. These bacteria can penetrate the dense matrix of solid tumors, reach the tumor core, and activate the host’s immune system, thereby enhancing their antitumor potential. Various species of oncolytic bacteria have been studied, including Salmonella, Escherichia coli, and Listeria, each of which has unique anticancer mechanisms and advantages.
Fig. 1 Promising attributes of oncolytic bacteria under development toward clinical translation for consideration to add further anti-cancer capacitie. (Roe, J. M., et al., 2023)
However, the development of oncolytic bacterial therapy faces numerous challenges:
OncoBact™ is a next-generation, precision-targeted oncolytic bacteria platform that revolutionizes cancer therapy by combining cutting-edge genetic engineering, microenvironment-responsive targeting, and dual-layer biosafety controls. Designed to address the limitations of conventional treatments, our platform leverages engineered bacterial vectors to deliver localized, synergistic anticancer effects while minimizing off-target risks.By leveraging CRISPR-based genetic engineering and synthetic biology tools, we engineer bacterial vectors to sense tumor-specific signals and dynamically activate therapeutic functions. Our platform’s three-layered innovation ensures precision and safety:
Precision Targeting
OncoBact™employs advanced genetic engineering to enable oncolytic bacteria to specifically respond to hypoxic and acidic conditions in the tumor microenvironment. This design ensures selective proliferation and lysis within tumor tissues while minimizing harm to healthy tissues, thereby enhancing therapeutic efficacy and reducing side effects.
Multimodal Payload Delivery System
The platform integrates multiple therapeutic modalities, including oncolytic activity, immunomodulation, and drug delivery. Oncolytic bacteria directly lyse tumor cells, release immune-activating factors to enhance antitumor immune responses, and carry chemotherapeutic agents or other therapeutic molecules for synergistic treatment effects, significantly improving overall therapeutic outcomes.
Dual-Layer Biosafety Control
OncoBact™ incorporates a dual-layer biosafety control system to ensure treatment safety. The first layer involves genetic modifications that prevent bacterial survival outside tumor tissues, while the second layer uses inducible systems to eliminate bacteria after treatment completion. This design effectively reduces off-target effects and side effects, enhancing the safety and reliability of the therapy.
The OncoBact™ platform offers the following significant advantages:
At Alfa Cytology, we are dedicated to advancing the field of oncolytic bacteria therapy through cutting-edge research and development. Our team of seasoned scientists and professionals is committed to leveraging the OncoBact™ platform to accelerate the development of innovative cancer treatments. We offer a comprehensive suite of services designed to support your projects at every stage. Here are the key services we provide:
Select for Alfa Cytology's one-stop oncolytic bacterial therapy development platform and embark on a hassle-free and efficient R&D journey. We offer a full-spectrum service, from bacterial strain screening and genetic engineering to preclinical trial design and execution. By integrating industry resources and assembling top-notch professional teams, we're dedicated to propelling your oncolytic bacterial therapy projects forward.
At Alfa Cytology's oncolytic bacteria-based combination therapy platform, we break the limitations of single-modality treatments. We artfully combine oncolytic bacterial therapy with other advanced treatment modalities, such as immunotherapy and radiotherapy. Through synergistic effects, we enhance treatment efficacy, offering innovative and comprehensive solutions to tackle complex cancer challenges
In the field of cancer therapy, Alfa Cytology, armed with cutting-edge technology and an innovative spirit, is dedicated to offering precise and efficient oncolytic bacteria therapy development services. We possess a professional R&D platform that provides one-stop development services for oncolytic bacteria therapy.
Starting with bacterial strain screening to accurately identify potential candidate strains, we then apply advanced genetic engineering in bacteria to endow them with remarkable antitumor properties. During the in vitro functional validation phase, we rigorously evaluate the anticancer activity of the engineered strains to ensure their effectiveness in the laboratory setting. Subsequently, through in vivo efficacy evaluation, we further verify their therapeutic potential in animal models.
Rigorously screen diverse bacterial strains to identify those with optimal oncolytic potential and safety profiles.
Employ advanced genetic engineering to modify selected bacteria for enhanced tumor targeting and therapeutic capabilities.
Conduct in vitro tests to validate the engineered bacteria's functionality and effectiveness against cancer cells.
Assess the engineered bacteria's anti-tumor efficacy in in vivo models.
At Alfa Cytology, we are at the forefront of oncolytic bacteria therapy innovation, and we are eager to collaborate with you to shape the future of cancer treatment. Our team of dedicated professionals is ready to assist you in leveraging our cutting-edge technology to develop groundbreaking therapies. If you're interested in the OncoBact™ platform, please contact us.
Reference
For research use only.
Alfa Cytology is a leading oncolytic bacteria technology platform provider, specializing in precision-targeted bacterial therapy development and end-to-end solution delivery.
Copyright © 2025 Alfa Cytology. All rights reserved.